

MARKET REPORT



Ulcerative Colitis: Update Bulletin #1

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Ulcerative Colitis: Update Bulletin #1

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Ulcerative Colitis: Update Bulletin #1

This edition presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include: Takeda and Portal Instruments announcing the production of a needle-free formulation of Entyvio (vedolizumab); Qu Biologics reporting that QBECO achieved high clinical and endoscopic response rates in a Phase II trial conducted in patients with moderate-to-severe UC; Protagonist Therapeutics announcing the initiation of dosing in a Phase I study of PTG 200, an agent which it is developing in collaboration with Janssen Biotech for inflammatory bowel disease (IBD) and other autoimmune conditions; Weill Cornell Medicine and NewYork-Presbyterian presenting results from a study investigating the use of faecal microbiota transplantation (FMT) in patients with UC.

Business Questions:

Are the new formulations of Entyvio likely to provide any benefit to patients with UC?

Is the development of both a needle-free and subcutaneous formulation of Entyvio necessary?

Does QBECO's composition, based on enteropathic Escherichia coli components, provide a rational basis for the agent's development as a UC therapy?

Where is PTG 200 most likely to be positioned within the UC treatment algorithm in the future?

Do KOLs think that the scientific rationale underlying FMT's activity supports its development as a treatment for UC and/or other diseases?

Do KOLs have any concerns about the safety of the FMT procedure?

Additional Details

Publisher : FirstWord Pharma

Reference :

Number of Pages : 0

Report Format : PDF

Publisher Information :

FirstWord

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Ulcerative Colitis: Update Bulletin #1

How to Buy...

Ulcerative Colitis: Update Bulletin #1

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/197049>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

\$931 | Single User Price

\$2274 | Global License Price

Payment Options: (please tick one)

Online Credit Card (we will email you the invoice with a payment link)

Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.